FDA Investigator Edward Deberry
Edward Deberry has inspections in 4 countries as of 24 Aug 2023. Edward Deberry has collaborated with a combined 3400 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
308
Last Inspection Date:
24 Aug 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
Hungary,
Italy,
Switzerland
Co-Investigator(s):
Aaron P Wozniak,
Abdur Rashid,
Adam R Cooke,
Alaric C Denton,
Allen F Hall,
Alphonso A Haupt, III,
Amanda L Evanco,
Amy A Johnson,
Amy H Ruble,
Ana L Kewes,
Anastasia M Shields,
Ann B Borromeo,
April R Bowen,
Arlyss M Jones,
Arthur G Hurst,
Babatunde D Babalola,
Betsy C Galliher,
Billy M Battles,
Bonita S Chester,
Brandy D Brown,
Brenda Rivera,
Brentley S Collins,
Brian A Graves,
Bridegan,
Brown,
Buford,
Burnell M Henry,
Carl A Anderson,
Carol F Robinson,
CDR Thomas R Berry, PPh,
Chapman,
Cherrie A Zachary,
Cherry R Valerio,
Cheryl D Barton,
Chestnut,
Christopher B May,
Christopher J Adams,
Christopher S Keating,
Claudette D Brooks,
Constance Y Fears,
Contractor Bridgers,
Cordelia J Brammer,
Crystal A Harlan,
Cynthia Jim, CSO,
D Ross Spears, PhD,
Daphne Santiago, PhD,
Darla J Christopher,
David J Leray,
David T Glover,
David Williams,
Davis,
Deborah A Greco,
Debra J Tucker,
Dellarese L Herbert,
Derek C Price,
Devaughn Edwards,
Dorothy P Kramer,
Douglas L Page,
Edecia A Richards,
Eileen J Bannerman,
Eliezar Ramos,
Eric S Weilage,
Erika M Wilkerson,
Ernest H Blackwood,
Esra Toussaint,
Fabian Nchaparro Rodriguez,
Gabriel R Mclemore,
Gamal A Norton,
Gary E Coleman, Jr, REHS,
Gates E Raynor,
Gideon N Esuzor,
Gray,
Hai Lien T Phung,
Helen R Bester,
Hristu B Chepa,
Hudson,
Ibad U Khan,
Igbinoba,
Ivery,
Ivy E Sweeney,
Jacqueline Mdiaz Albertini,
James P Lewis, Jr,
Janet B Gray,
Jared P Stevens,
Jason F Chancey,
Jason K Morgan,
Jawaid Hamid,
Jeffrey D Sheppard,
Jennifer L Bridgewater,
Jimmy O Buford,
John D Lloyd,
John E Aghadia,
Johnson,
Joseph F Owens,
Julie D Bringger,
Justin A Boyd,
Kemejumaka N Opara,
Kenny R Robinson,
Kewes,
Kimberly Cdelk Brooks,
Kip J Hanks,
Kunapuli T Madhusudhan,
Lareese K Thomas,
Larry K Hampton,
Laurice Mccoy,
Lawrence,
Lawrence S Newsom,
Lesley K Satterwhite,
Leslie W Gilbert,
Libia M Lugo,
Lillie D Witcher,
Mancia R Walker,
Marc A Alston,
Marcella D Crook,
Margaret Torres Vazquez,
Marie F Morin,
Mark C Saale,
Marla A Cassidy,
Mary Alice Papdimitriou,
Mary F Bodick,
Marybeth Willis,
Matthew G Brown,
Maya M Davis,
Mcbean,
Melanie M Walker,
Metitia G Sanders,
Metitia M Gramby,
Miaja Umaedi,
Michelle D Haamid,
Michelle L Jones,
Mihaly S Ligmond,
Mokhless A Ghaly,
Morrell,
Nancy E Fontaine,
Nicholas M Smith,
Nicole A Lloyd,
Nicole D Lyons,
Pamela L Vega,
Panney H Mccarver,
Paul A Bonneau,
Paula J Bretz,
Penny H Mccarver,
Perry H Gambrell,
Prabhu P Raju,
R Edwadebey Deberry,
Rachael L Cook,
Radona R Boutte,
Randy L Clarida,
Rashard A Knight,
Rashonda N Rucker,
Rebecca Rodriguez,
Richard J Bashay,
Richard L Garcia,
Robert C Coleman,
Robert D Tollefsen,
Robert J Rutherford,
Robert Q Green,
Robert W Turner,
Robin N Goins,
Russell K Riley,
Sally Gopaul,
Sandra I Gaul,
Sandra R Saunders,
Scott T Ballard,
Seneca D Toms,
Sereen Gmorgan Murray,
Shayla G Turnipseed,
Shusheen A Alexander,
Simone M Edmonson,
Siobhan G Taylor,
Smith,
Sonya M Edmonds,
Stanley Nelson,
State Agency,
Stephanie E Hubbard,
Stephanie L Kelly,
Stephen D Brown,
Steven M Weinman,
Susan M Taylor,
Tallman,
Tamara M Casselman,
Tammara A Newberry,
Tammara A Stephens,
Theresa L Stewart,
Timothy T Kapsala,
Tomika L Bivens,
Tracy K Bell,
Tracy L Ramseur,
Tracy R Ball,
Tyrico K English,
Vanessa E Coulter,
Veronica Fuentes, MS,
Vicky C Stoakes,
Victoria L Palmer,
Vincent M Williams,
Viviana Matta,
Walker,
Washington,
Watson,
Weedb,
William P Tonkins,
Williams,
Young Kim
Edward Deberry's Documents
Publish Date | Document Type | Title |
---|---|---|
September, 2009 | EIR | Nypro Inc. - EIR, 2009-09-09 |
June, 2010 | EIR | Greer Laboratories, Inc. - EIR, 2010-06-29 |
September, 2015 | FDA 483 | King Bio Inc. - Form 483, 2015-09-04 |
September, 2008 | EIR | Greer Laboratories, Inc. - EIR, 2008-09-15 |
September, 2007 | EIR | Baxter Healthcare Corporation - EIR, 2007-09-19 |
September, 2006 | EIR | Greer Laboratories, Inc. - EIR, 2006-09-18 |
September, 2012 | EIR | Nypro Inc. - EIR, 2012-09-12 |
September, 2008 | FDA 483 | King Bio Inc. - Form 483, 2008-09-25 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more